Pharmacopsychiatry 2003; 36 - 31
DOI: 10.1055/s-2003-825282

Decrease of amyloid β1–42 antibodies in serum of patients with Alzheimer's disease

S Brettschneider 1, N Morgenthaler 2, SJ Teipel 1, C Fischer-Schulz 2, K Bürger 1, HJ Möller 1, A Bergmann 2, H Hampel 1
  • 1Department of Psychiatry, Ludwig-Maximilian Universität, München
  • 2BRAHMS AG, Research Department, Biotechnological Center Henningsdorf Berlin

Amyloid β (Aβ) is the histopathological hallmark of Alzheimer’s disease (AD). Antibodies against Aβ occur naturally and are used in promising therapeutical approaches. To assess the diagnostic value of serum Aβ-antibodies for AD, we compared serum Aβ-antibody levels of 96 patients with AD, 14 with Frontotemporal Dementia, 8 with Lewy-Body-Dementia, 18 with Vascular Dementia (VD), 31 with Major Depression (MD) and of 30 healthy controls (HC) using a newly developed immunoassay by Brahms. We found a highly significant decrease of Aβ-antibody levels in AD compared to HC (p=0,001) independently of age, cognitive status and ApoEε4-carrier-status. Aβ-antibody levels correlated to gender in AD with higher levels in women. Applying ROC-Analysis, sensitivity/ specificity was 81,3%/46,7% comparing patients with AD to HC. There was no significant difference of Aβ-antibody levels comparing AD to Non-AD-Dementia or MD. Serum Aβ-antibodies may be related to AD, but appear not to be a useful diagnostic marker for AD.


Dodel R, Hampel H, Du Y. Immunotherapy for Alzheimer’s disease. Lancet Neurology 2003; 2: 215–220.

Du Y, dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Fralow M, Paul S. Reduced levels of amyloid β-peptide antibody in Alzheimer’s disease. Neurology 2001; 57:801–805.

Dodel R, hampel H, Candan D, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, DuY. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol 2002; 52: 253–256.